References

Bahar, M. E., Kim, H. J., & Kim, D. R. (2023). Targeting the RAS/RAF/MAPK pathway for cancer therapy: From mechanism to clinical studies. *Signal Transduction and Targeted Therapy*, *8*(1). https://doi.org/10.1038/s41392-023-01705-z

Bai, X., Sun, P., Wang, X., Long, C., Liao, S., Dang, S., Zhuang, S., Du, Y., Zhang, X., Li, N., He, K., & Zhang, Z. (2023). Structure and dynamics of the EGFR/HER2 heterodimer. *Cell Discovery*, *9*(1). https://doi.org/10.1038/s41421-023-00523-5

Barros, F., Powe, D. G., Ellis, I. O., & Green, A. (2010). Understanding the HER family in breast cancer: Interaction with ligands, dimerization and treatments. *Histopathology*, *56*(5), 560–572. https://doi.org/10.1111/j.1365-2559.2010.03494.x

Best, R. L., LaPointe, N. E., Azarenko, O., Miller, H., Genualdi, C., Chih, S., Shen, B.-Q., Jordan, M. A., Wilson, L., Feinstein, S. C., & Stagg, N. J. (2021). Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy. *Toxicology and Applied Pharmacology*, *421*, 115534. https://doi.org/10.1016/j.taap.2021.115534

Bhakta-Yadav, M. S., & Brown, T. L. (2025). Important aspects of siRNA design for optimal efficacy in vitro and in vivo. *International Journal of Cell Biology*, *2025*(1). https://doi.org/10.1155/ijcb/6663816

Cai, X., Zhang, L., & Chen, S. (2022). Editorial: Cancer treatment and early detection targeting HER receptors. *Frontiers in Molecular Biosciences*, *9*. https://doi.org/10.3389/fmolb.2022.940055

Chen, W., Gupta, A., Mai, N., Nag, S., Lau, J. S., Singh, S., Chodera, J. D., Liu, B., de Stanchina, E., Pareja, F., Hashmi, A. Ali., Lieberman, M. M., Modi, S., Bromberg, J., Razavi, P., Drago, J. Z., & Chandarlapaty, S. (2025). Trastuzumab deruxtecan (t-dxd) resistance via loss of HER2 expression and binding. *Cancer Discovery*. https://doi.org/10.1158/2159-8290.cd-25-0647

Cheng, X. (2024). A comprehensive review of HER2 in cancer biology and therapeutics. *Genes*, *15*(7), 903–903. https://doi.org/10.3390/genes15070903

Chiang, W. F., Cheng, T. M., Chang, C. C., Pan, S. H., Changou, C. A., Chang, T. H., Lee, K. H., Wu, S. Y., Chen, Y. F., Chuang, K. H., Shieh, D. B., Chen, Y. L., Tu, C. C., Tsui, W. L., & Wu, M. H. (2018). Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) promotes EGF receptor signaling of oral squamous cell carcinoma metastasis via the complex N-glycosylation. *Oncogene*, *37*(1), 116–127. https://doi.org/10.1038/onc.2017.303

Ćorović, M., Hoch-Kraft, P., Zhou, Y., Hallstein, S., König, J., & Zarnack, K. (2025). M6A in the coding sequence: Linking deposition, translation, and decay. *Trends in Genetics*, *41*(11), 963–973. https://doi.org/10.1016/j.tig.2025.06.002

Cretella, D., Saccani, F., Quaini, F., Frati, C., Lagrasta, C., Bonelli, M., Caffarra, C., Cavazzoni, A., Fumarola, C., Galetti, M., La Monica, S., Ampollini, L., Tiseo, M., Ardizzoni, A., Petronini, P. G., & Alfieri, R. R. (2014). Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance. *Molecular Cancer*, *13*(1). https://doi.org/10.1186/1476-4598-13-143

El-Gamal, M. I., Mewafi, N. H., Abdelmotteleb, N. E., Emara, M. A., Tarazi, H., Sbenati, R. M., Madkour, M. M., Zaraei, S.-O., Shahin, A. I., & Anbar, H. S. (2021). A review of HER4 (erbb4) kinase, its impact on cancer, and its inhibitors. *Molecules*, *26*(23), 7376. https://doi.org/10.3390/molecules26237376

European Medicines Agency. (2025). *Enhertu (trastuzumab deruxtecan)*. https://www.ema.europa.eu/en/documents/overview/enhertu-epar-medicine-overview_en.pdf

Ferguson, K. M. (2008). Structure-Based view of epidermal growth factor receptor regulation. *Annual Review of Biophysics*, *37*(1), 353–373. https://doi.org/10.1146/annurev.biophys.37.032807.125829

Fuchs, A., Riegler, S., Ayatollahi, Z., Cavallari, N., Giono, L. E., Nimeth, B. A., Mutanwad, K. V., Schweighofer, A., Lucyshyn, D., Barta, A., Petrillo, E., & Kalyna, M. (2021). Targeting alternative splicing by RNAi: From the differential impact on splice variants to triggering artificial pre-mRNA splicing. *Nucleic Acids Research*, *49*(2), 1133–1151. https://doi.org/10.1093/nar/gkaa1260

Galogre, M. I., Rodin, D., Pyatnitskiy, M. A., Mackelprang, M., & Koman, I. (2023). A review of HER2 overexpression and somatic mutations in cancers. *Critical Reviews in Oncology/Hematology*, *186*, 103997–103997. https://doi.org/10.1016/j.critrevonc.2023.103997

Gogia, P., Ashraf, H., Bhasin, S., & Xu, Y. (2023). Antibody–Drug conjugates: A review of approved drugs and their clinical level of evidence. *Cancers*, *15*(15), 3886–3886. https://doi.org/10.3390/cancers15153886

Greenblatt, K., & Khaddour, K. (2020). *Trastuzumab*. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK532246/

He, J., Zeng, X., Wang, C., Wang, E., & Li, Y. (2024). Antibody-drug conjugates in cancer therapy: Mechanisms and clinical studies. *MedComm*, *5*(8), e671. https://doi.org/10.1002/mco2.671

He, Y., Sun, M. M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021). Targeting PI3K/AKT signal transduction for cancer therapy. *Signal Transduction and Targeted Therapy*, *6*(1), 1–17. https://doi.org/10.1038/s41392-021-00828-5

Hsu, J. L., & Hung, M.-C. (2016). The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. *Cancer and Metastasis Reviews*, *35*(4), 575–588. https://doi.org/10.1007/s10555-016-9649-6

Johnson, B., & Mahadevan, D. (2015). Emerging role and targeting of carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) in human malignancies. *Clinical Cancer Drugs*, *2*(2), 100–111. https://doi.org/10.2174/2212697x02666150602215823

Kennedy, S. P., Hastings, J. F., Han, J. Z. R., & Croucher, D. R. (2016). The under-appreciated promiscuity of the epidermal growth factor receptor family. *Frontiers in Cell and Developmental Biology*, *4*. https://doi.org/10.3389/fcell.2016.00088

Kim, E. Y., Cha, Y. J., Jeong, S., & Chang, Y. S. (2022). Overexpression of CEACAM6 activates src-fak signaling and inhibits anoikis, through homophilic interactions in lung adenocarcinomas. *Translational Oncology*, *20*, 101402. https://doi.org/10.1016/j.tranon.2022.101402

Kim, S. H., Park, Y., Min, A., Park, H. Y., Kim, Y.-J., Ham, S., Koh, J., Kim, S., Lee, D.-W., Ryu, H. S., Kim, J.-S., Lee, K.-H., & Im, S.-A. (2026). DNA damage and nuclear anaplasia induced by trastuzumab deruxtecan in cancer cells with variable HER2 expression and homologous recombination deficiency status. *Cancer Research and Treatment*, *58*(2), 407–422. https://doi.org/10.4143/crt.2025.201

Luque-Cabal, M., García-Teijido, P., Fernández-Pérez, Y., Sánchez-Lorenzo, L., & Palacio-Vázquez, I. (2016). Mechanisms behind the resistance to trastuzumab in her2-amplified breast cancer and strategies to overcome it. *Clinical Medicine Insights: Oncology*, *10s1*, CMO.S34537. https://doi.org/10.4137/cmo.s34537

Lyu, H., Han, A., Polsdofer, E., Liu, S., & Liu, B. (2018). Understanding the biology of HER3 receptor as a therapeutic target in human cancer. *Acta Pharmaceutica Sinica B*, *8*(4), 503–510. https://doi.org/10.1016/j.apsb.2018.05.010

Maadi, H., Soheilifar, M. H., Choi, W.-S., Moshtaghian, A., & Wang, Z. (2021). Trastuzumab mechanism of action; 20 years of research to unravel a dilemma. *Cancers*, *13*(14), 3540. https://doi.org/10.3390/cancers13143540

Mashayekh-Poul, R., Azimzadeh-Irani, M., & Masoomi-Nomandan, S. Z. (2023). Structural arrangement of the active back-to-back dimer in N-glycosylated ErbB receptors is regulated by heterodimerization. *Molecular Biology Research Communications*, *12*(3), 95–107. https://doi.org/10.22099/mbrc.2023.47147.1822

Mercogliano, M. F., De Martino, M., Venturutti, L., Rivas, M. A., Proietti, C. J., Inurrigarro, G., Frahm, I., Allemand, D. H., Deza, E. G., Ares, S., Gercovich, F. G., Guzmán, P., Roa, J. C., Elizalde, P. V., & Schillaci, R. (2016). TNFα-Induced mucin 4 expression elicits trastuzumab resistance in her2-positive breast cancer. *Clinical Cancer Research*, *23*(3), 636–648. https://doi.org/10.1158/1078-0432.ccr-16-0970

Miao, Y., Du, Q., Zhang, H., Yuan, Y., Zuo, Y., & Zheng, H. (2023). Cycloheximide (CHX) chase assay to examine protein half-life. *Bio-Protocol*, *13*(11). https://doi.org/10.21769/bioprotoc.4690

Ouyang, Q., Tian, C., Gao, J., Huang, J., Fu, H., He, J., & Yang, J. (2016). HER2-positive double primary tumor of gastric and breast cancer occur synchronously in a patient: A case report. *Molecular and Clinical Oncology*, *4*(5), 719–722. https://doi.org/10.3892/mco.2016.812

Pan, L., Li, J., Xu, Q., Gao, Z., Yang, M., Wu, X., & Li, X. (2024). HER2/PI3K/AKT pathway in HER2-positive breast cancer: A review. *Medicine*, *103*(24), e38508–e38508. https://doi.org/10.1097/md.0000000000038508

Park, M.-Y., Jung, M. H., Eo, E. Y., Kim, S., Lee, S. H., Lee, Y. J., Park, J. S., Cho, Y. J., Chung, J. H., Kim, C. H., Yoon, H. I., Lee, J. H., & Lee, C.-T. (2017). Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing. *Oncotarget*, *8*(22). https://doi.org/10.18632/oncotarget.16752

Popović, L., Wintgens, J. P., Wu, Y., Brankatschk, B., Menninger, S., Degenhart, C., Jensen, N., Wichert, S. P., Klebl, B., Rossner, M. J., & Wehr, M. C. (2024). Profiling of ERBB receptors and downstream pathways reveals selectivity and hidden properties of ERBB4 antagonists. *IScience*, *27*(2), 108839–108839. https://doi.org/10.1016/j.isci.2024.108839

Roskoski, R. (2014). The ErbB/HER family of protein-tyrosine kinases and cancer. *Pharmacological Research*, *79*, 34–74. https://doi.org/10.1016/j.phrs.2013.11.002

Sassen, A., Rochon, J., Wild, P., Hartmann, A., Hofstaedter, F., Schwarz, S., & Brockhoff, G. (2008). Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. *Breast Cancer Research*, *10*(1). https://doi.org/10.1186/bcr1843

Sledge, G. W., Xiu, J., Mahtani, R. L., Sandoval, A. C., Meric-Bernstam, F., Ribeiro, J. R., Kulkarni, N. N., Rampa, D. R., Lee, J., Ueno, N. T., Oberley, M. J., Radovich, M., & Spetzler, D. B. (2025). Mechanisms of resistance to trastuzumab deruxtecan in breast cancer elucidated by multi-omic molecular profiling. *Npj Breast Cancer*, *12*(1), 1–1. https://doi.org/10.1038/s41523-025-00868-y

Swain, S. M., Shastry, M., & Hamilton, E. (2022). Targeting her2-positive breast cancer: Advances and future directions. *Nature Reviews Drug Discovery*, *22*(2), 1–26.

Topalan, E., Büyükgüngör, A., Çiğdem, M., Güra, S., Sever, B., Otsuka, M., Fujita, M., Demirci, H., & Ciftci, H. (2025). A structural insight into two important erbb receptors (EGFR and HER2) and their relevance to non-small cell lung cancer. *Archiv Der Pharmazie*, *358*(4). https://doi.org/10.1002/ardp.202400992

Vu, T., & Claret, F. X. (2012). Trastuzumab: Updated mechanisms of action and resistance in breast cancer. *Frontiers in Oncology*, *2*(62). https://doi.org/10.3389/fonc.2012.00062

Waight, A. B., Bargsten, K., Doronina, S., Steinmetz, M. O., Sussman, D., & Prota, A. E. (2016). Structural basis of microtubule destabilization by potent auristatin anti-mitotics. *PLoS ONE*, *11*(8), e0160890. https://doi.org/10.1371/journal.pone.0160890

Wang, L., Wang, Y., Li, Y., Zhou, L., Du, J., Wang, J., Liu, S., Cao, Y., Li, Y., Yang, W., & Zhu, T. (2024). Resistance mechanisms and prospects of trastuzumab. *Frontiers in Oncology*, *14*. https://doi.org/10.3389/fonc.2024.1389390

Wang, Y., Cheng, X., Li, X., Chen, W., Zhang, X., & Liu, Y. (2025). Bystander effect in antibody-drug conjugates: Navigating the fine line in tumor heterogeneity. *Critical Reviews in Oncology/Hematology*, *216*, 104979. https://doi.org/10.1016/j.critrevonc.2025.104979

Xie, H., Wang, X., Zhang, P., Li, Q., & Chen, J. (2026). Innovations in HER2-targeted therapy: A comprehensive review of trastuzumab deruxtecan. *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer*, *1881*(2), 189550. https://doi.org/10.1016/j.bbcan.2026.189550

Xu, X.-M., Yoo, M.-H., Carlson, B. A., Gladyshev, V. N., & Hatfield, D. L. (2009). Simultaneous knockdown of the expression of two genes using multiple shRNAs and subsequent knock-in of their expression. *Nature Protocols*, *4*(9), 1338–1348. https://doi.org/10.1038/nprot.2009.145

Yan, M., Schwaederle, M., Arguello, D., Millis, S. Z., Gatalica, Z., & Kurzrock, R. (2015). HER2 expression status in diverse cancers: review of results from 37,992 patients. *Cancer Metastasis Reviews*, *34*, 157–164. https://doi.org/10.1007/s10555-015-9552-6

Zhao, X., Li, Y., Zhang, H., Cai, Y., Wang, X., Liu, Y., Li, T., Xu, C., Teng, Y., Li, D., & Li, F. (2025). PAK5 promotes the trastuzumab resistance by increasing HER2 nuclear accumulation in HER2-positive breast cancer. *Cell Death and Disease*, *16*(1). https://doi.org/10.1038/s41419-025-07657-2

Zheng, M.-Y., Lin, Y.-T., Kuo, Y.-S., Lin, Y.-J., Kuo, M.-H., Huang, T.-W., Shieh, Y.-S., Huang, Y., & Chou, Y.-T. (2025). Cytokine and epigenetic regulation of CEACAM6 mediates EGFR-driven signaling and drug response in lung adenocarcinoma. *Npj Precision Oncology*, *9*(1). https://doi.org/10.1038/s41698-025-00910-z

Zhu, M., Yu, M., Meng, Y., Yang, J., Wang, X., LI, L., Liang, Y., & Kong, F. (2024). HER3 receptor and its role in the therapeutic management of metastatic breast cancer. *Journal of Translational Medicine*, *22*(1). https://doi.org/10.1186/s12967-024-05445-8